The U.S. Food and Drug Administration announced on October 19 that Jessica Zeller will become the next director of the Center for Tobacco Products’ Office of Compliance and Enforcement, effective November 1, 2026. 

The appointment puts a returning FDA official in a significant leadership position for the tobacco and vaping industry. It also comes as manufacturers and retailers look for clearer rules, more predictable enforcement and a more efficient product review process. 

 

A Return to Tobacco Enforcement 

According to FDA’s announcement, Zeller previously served as the office’s inaugural deputy director, helping direct nationwide compliance and enforcement efforts. 

She returns from Edwards Lifesciences, where she served as vice president corporate counsel and general counsel for quality. Her background includes more than 20 years in compliance, enforcement, legal and regulatory affairs, along with other positions in FDA’s regulatory and legal offices. 

 

What Does the Office Do? 

CTP’s compliance and enforcement work directly affects manufacturers, importers, distributors and retailers. 

FDA monitors whether businesses comply with federal tobacco requirements, including restrictions on sales to underage purchasers and requirements governing the marketing of tobacco products. Its tools include inspections, warning letters and enforcement actions. 

For unauthorized tobacco products, potential actions include civil money penalties, seizures and injunctions. FDA explains that it generally issues a warning letter before initiating enforcement, although a warning letter is not legally required first. 

That makes enforcement leadership relevant throughout the supply chain. The office’s work reaches beyond product manufacturers to the businesses distributing and selling those products. 

 

Enforcement and Product Review Both Matter 

The appointment arrives during an ongoing discussion about how FDA can make its tobacco product review process more efficient. 

In a May 7 statement, CTP Acting Director Bret Koplow outlined efforts to accelerate application reviews, improve communication with applicants and apply lessons from the agency’s nicotine pouch pilot program more broadly. 

FDA also acknowledged the connection between efficient reviews and making products that meet the statutory public health standard available to adult tobacco users who might reduce their health risks by using them. 

From an industry perspective, those goals need to work together. Businesses need understandable compliance expectations and a workable process for obtaining marketing authorization. Enforcement decisions carry real consequences for inventory, investment and the choices available to adult consumers. 

 

Does This Appointment Change FDA Policy? 

The personnel announcement does not announce a new enforcement policy, authorize additional products or revise application requirements. It identifies the incoming director, describes her experience and establishes her start date. 

It would therefore be premature to describe the appointment as evidence of either a tougher crackdown or a more flexible approach. 

The more useful question is what FDA does next. 

 

What Vape Businesses Should Watch 

As the leadership transition takes effect, several developments will be worth following: 

• Written enforcement guidance: Whether FDA publishes changes explaining how it prioritizes products and businesses. 

• Communication with industry: Whether manufacturers, distributors and retailers receive clearer answers about compliance expectations. 

• Product review progress: Whether announced efficiency efforts produce timely decisions and more predictable application reviews. 

• Consistency: Whether FDA’s public statements, guidance and enforcement actions give businesses a coherent picture of the agency’s approach. 

These are points to monitor, rather than outcomes established by the appointment. 

For independent vape businesses, the standard should be straightforward: clear expectations, fair treatment and a realistic opportunity to bring qualifying products through the review process. 

Zeller’s return is a leadership development worth watching. Its practical significance will become clearer through the decisions and policies that follow.